The abstract is read at the publisher; the summary is JClub's.
Rifaximin use in cirrhosis is linked to selection of antimicrobial resistance genes and rifaximin-resistant Enterobacter spp, with cross-resistance in Enterococcus faecium to last-line agents.
- Why it matters: Evidence has not kept pace with therapeutic drift, and new microbiological and epidemiological findings challenge rifaximin’s perceived benign gut-modulating role in cirrhosis.
- What they did: The Viewpoint reviews randomized trial results showing no benefit for primary prevention of hepatic encephalopathy or prevention of acute-on-chronic liver failure, alongside emerging microbiological and epidemiological data on resistance.
- The result: It argues for recalibrating rifaximin to evidence-based indications and embedding antimicrobial stewardship into hepatology guidelines and policy to address public health concerns.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.